• Sublimity hires new CMO as it advances UC candidate in phase 2 fiercebiotech
    August 01, 2018
    Ulcerative colitis specialist Sublimity Therapeutics brought on Jesse Hall, M.D., to be its new chief medical officer, as the company looks to advance the clinical development of its lead candidate into a phase 2b study.
PharmaSources Customer Service